References
- Wools-Kaloustian K, Kimaiyo S. Extending HIV care in resource-limited settings. Curr. HIV/AIDS Rep.3(4), 182–186 (2006).
- WHO. Overview of the global AIDS epidemic. In: 2006 Report on the Global AIDS Epidemic (2006).
- Kuroda MJ, Schmitz JE, Charini WA et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol.162(9), 5127–5133 (1999).
- Koup R, Safrit J, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol.68(7), 4650–4655 (1994).
- Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science272(5265), 1167–1170 (1996).
- Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature327(6122), 473–476 (1987).
- Egan MA. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection. AIDS Res. Hum. Retroviruses20(8), 794–806 (2004).
- Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J. Int. Med.261(2), 123–131 (2007).
- Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med.10(12), 1359–1365 (2004).
- MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J. Infect. Dis.181(1), 406 (2000).
- MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis.178(1), 92–100 (1998).
- Boyer JD, Chattergoon MA, Ugen KE et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin. Immunol.90(1), 100–107 (1999).
- Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet351(9112), 1320–1325 (1998).
- Calarota SA, Leandersson AC, Bratt G et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. Immunol.163(4), 2330–2338 (1999).
- Gronevik E, Mathiesen I, Lomo T. Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J. Gene Med.7(9), 1246–1254 (2005).
- Luckay A, Sidhu MK, Kjeken R et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol.81(10), 5257–5269 (2007).
- Kjeken R, Tjelle T, Kvale D, Mathiesen I. Clinical evaluation of pain and muscle damage induced by electroporation of skeletal muscle in humans. Mol. Ther.9(Suppl. 157), S60 (2004).